TTI Stock Discussion
Thiogenesis Therapeutics, Corp Description
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of a range of unmet genetic and central nervous system diseases. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine and pantetheine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke. The company is headquartered in Toronto, Canada.
Industry: Biotechnology
Keywords: Biopharmaceutical Stroke
Recent Comments
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
From the Blog
Popular Now
Featured Articles